levodopa has been researched along with paroxetine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Colado, MI; Esteban, B; Granados, R; Green, AR; Martín, AB; O'Shea, E | 1 |
| Brenninkmeijer, JH; Freijzer, PL | 1 |
| Steur, EN | 1 |
| Schölzel-Dorenbos, CJ | 1 |
| Carlson, NE; Chung, KA; Nutt, JG | 1 |
| Corbeil, P; McDonald, J; Pourcher, E | 1 |
| Bishop, C; Buchta, W; Dickinson, SO; Eissa, S; Eskow Jaunarajs, KL; George, JA; Goldenberg, AA; Mohamed, M | 1 |
| Campos, FL; Carvalho, MM; Coimbra, B; Lima, R; Pêgo, JM; Rodrigues, AJ; Rodrigues, C; Salgado, AJ; Sousa, N | 1 |
| Bishop, C; Conti, MM; Dell'isola, R; Goldenberg, AA; Kampton, E; Katzman, AC; Lindenbach, D; Ostock, CY | 1 |
1 trial(s) available for levodopa and paroxetine
| Article | Year |
|---|---|
Short-term paroxetine treatment does not alter the motor response to levodopa in PD.
Topics: Accidental Falls; Aged; Brain; Cross-Over Studies; Dizziness; Dopamine; Dopamine Agents; Double-Blind Method; Drug Interactions; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Paroxetine; Presynaptic Terminals; Selective Serotonin Reuptake Inhibitors; Serotonin; Treatment Failure; Vestibular Diseases | 2005 |
14 other study(ies) available for levodopa and paroxetine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.
Topics: Animals; Body Temperature; Brain; Dopamine; Free Radicals; Haloperidol; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Neurodegenerative Diseases; Paroxetine; Rats; Serotonin | 1999 |
[Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Interactions; Drug Therapy, Combination; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
[Hallucinations caused by paroxetine in combined usage of levodopa-carbidopa].
Topics: Antidepressive Agents, Second-Generation; Antiparkinson Agents; Carbidopa; Drug Interactions; Hallucinations; Levodopa; Parkinson Disease; Paroxetine | 2002 |
[Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Synergism; Drug Therapy, Combination; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
Balance control improves following replacement of paroxetine with venlafaxine and levodopa in a case of microvascular dementia.
Topics: Aged, 80 and over; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Cyclohexanols; Dementia, Vascular; Diagnosis, Computer-Assisted; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Microvessels; Paroxetine; Postural Balance; Venlafaxine Hydrochloride | 2011 |
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Biogenic Monoamines; Citalopram; Corpus Striatum; Dyskinesia, Drug-Induced; Fluoxetine; Levodopa; Male; Parkinsonian Disorders; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2012 |
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion; Disease Models, Animal; Immunohistochemistry; Levodopa; Mood Disorders; Motor Activity; Oxidopamine; Parkinsonian Disorders; Paroxetine; Rats; Rats, Wistar | 2013 |
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Citalopram; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2014 |